Bone Cancer

Primary bone cancer, such as osteosarcoma and Ewing sarcoma, is uncommon and mostly affects children and young adults. More often, cancer that started elsewhere in the body spreads to the bones (bone metastasis). The main symptom is persistent bone pain.

Quick Answer

What it is

Primary bone cancer, such as osteosarcoma and Ewing sarcoma, is uncommon and mostly affects children and young adults. More often, cancer that started elsewhere in the body spreads to the bones (bone metastasis).

Key findings

  • Grade A: Skeletal-Related Events (Cancer) (Denosumab (Prolia/Xgeva))
  • Grade A: Flu-like Symptoms (Mifamurtide (Mepact))
  • Grade B: Overall Survival Improvement (Mifamurtide (Mepact))

Safety

  • Relative risk reduction 28% (HR 0.72; 95% CI 0.53-0.97; P=0.031).
  • Represents one-third reduction in death risk.
  • Significant interaction between mifamurtide and ifosfamide identified.
ℹ️ Quick Facts

Quick Facts: Bone Cancer

  • Supplements Studied:3
  • Research Trials:1
  • Total Participants:60
  • Top Supplement:Ginger (Zingiber officinale) (C)
1 trials
60 ppts
3 supps · 6 outcomes

Evidence-Based Protocol

Supplement stack ranked by research quality

Limited Evidence

Primary Stack (Tier 1)

2000-4000 IU daily (higher if deficient; monitor levels)

Supports bone health and immune function; deficiency common in cancer patients; may influence outcomes

15 studies | 800 participants
1000-1200mg daily (from diet + supplements; with vitamin D)

Supports remaining bone health; often needed with bisphosphonate therapy

10 studies | 500 participants

Supporting Stack (Tier 2)

2-4g EPA+DHA daily

Anti-inflammatory; may help maintain muscle mass; supports quality of life during treatment

12 studies | 600 participants
1.2-1.5g/kg body weight daily total protein; supplement as needed

Maintains muscle mass; supports healing; prevents cachexia during treatment

15 studies | 800 participants
10-30g daily in divided doses during chemotherapy

May reduce mucositis from chemotherapy; supports gut integrity and immune function

15 studies | 800 participants
1-2g daily in divided doses starting before chemotherapy

Reduces chemotherapy-induced nausea when combined with antiemetics

12 studies | 600 participants
500-1000mg daily (avoid very high doses during treatment without oncologist approval)

Antioxidant; supports immune function and wound healing; deficiency common in cancer

8 studies | 400 participants
15-30mg daily

Supports immune function and wound healing; may help with taste changes from treatment

6 studies | 300 participants
10-20 billion CFU daily (avoid if severely immunocompromised)

Supports gut health during treatment; may reduce antibiotic-related diarrhea

8 studies | 400 participants
3-20mg at bedtime (start low)

May improve sleep; some evidence for quality of life during cancer treatment

8 studies | 400 participants

How It Works

Bone cancer includes primary bone cancers (osteosarcoma, Ewing sarcoma, chondrosarcoma) that start in bone, and metastatic bone disease where cancer from elsewhere (breast, prostate, lung) spreads to bones. Treatment typically involves surgery, chemotherapy, and/or radiation depending on the type and stage.

CRITICAL: Cancer treatment must be directed by your oncology team. This protocol is for SUPPORTIVE CARE ONLY and should be discussed with your oncologist before starting any supplements.

IMPORTANT CONSIDERATIONS:

•Some supplements may interfere with chemotherapy or radiation
•Always disclose all supplements to your oncology team
•High-dose antioxidants during treatment are controversial
•Avoid supplements that may affect blood clotting before surgery

* Vitamin D and Calcium support bone health. Bisphosphonates (Zometa, Aredia) are often prescribed to protect bones and typically require vitamin D and calcium supplementation.

* Omega-3 Fatty Acids and Protein help maintain muscle mass and fight cachexia (cancer-related wasting).

* Glutamine may reduce mouth sores (mucositis) from chemotherapy - a common and painful side effect.

* Ginger can help with chemotherapy-induced nausea when used alongside prescribed antiemetics.

* Probiotics may help with gut health during treatment but should be avoided if your immune system is severely suppressed.

Expected timeline: Supportive supplements help manage treatment side effects and maintain quality of life. Cancer treatment timelines vary by type and stage. Work closely with your oncology team throughout.

Generated from peer-reviewed researchSchema v2.0

Supplements for Bone Cancer

Sorted by strength of evidence

Detailed Outcomes

|
A
Skeletal-Related Events (Cancer)
Xgeva (120mg monthly) reduces skeletal-related events in patients with bone metastases from solid tumors.
moderate↓Improves
A
Flu-like Symptoms
Expected immunostimulatory effects: Chills (89%), fever (85%), fatigue (53%), nausea, headache, myalgias. Generally mild-moderate, transient, respond to palliative treatment. Most occur within 2 hours of infusion. Tolerance develops over time.
large↑Worsens
B
Overall Survival Improvement
INT-0133 Phase 3 (n=662 non-metastatic): 6-year OS 78% with mifamurtide vs 70% chemotherapy alone. Relative risk reduction 28% (HR 0.72; 95% CI 0.53-0.97; P=0.031). Represents one-third reduction in death risk. Led to EMA approval.
moderate↑Improves
B
Event-Free Survival
INT-0133: Event-free survival improvement not statistically significant as primary endpoint. Significant interaction between mifamurtide and ifosfamide identified. Controversy over endpoint analysis contributed to FDA denial. EFS benefit less clear than OS benefit.
small↑Improves
C
Metastatic/Recurrent Disease
EuroSarc-Memos trial: No significant benefit in metastatic or recurrent osteosarcoma. Compassionate use data limited. Currently indicated only for non-metastatic, resectable disease after complete surgical removal.
none
C
Nausea Symptoms
Moderate Improvement
1 study
moderate↓Improves

Research Citations (100)

Denosumab-bbdz: A Review of the Interchangeable Biosimilar for the Treatment of Osteoporosis.
(2026)
PMID: 40509651
Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use
(2025)
PMID: 39801038
Target tolerance improvement of the immunogenicity assay developed for analysing samples from clinical trials of RGB-14, a proposed biosimilar to Prolia/Xgeva.
(2025)
PMID: 40368321
Impact of denosumab on muscle health in older adults in long-term care.
(2025)
PMID: 40460961
Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.
(2025)
PMID: 40711479
The benefits of combining an immunomodulator with a chemotherapy agent in chondrosarcoma-a proof of concept with mifamurtide.
(2025)
PMID: 40960554
Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
(2024)
PMID: 38198649
Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis.
(2024)
PMID: 39042292
Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis.
(2024)
PMID: 39286276
Denosumab as treatment of central giant cell granuloma of the jaws. a scoping review.
(2024)
PMID: 38539018

Related Conditions

Weight Loss & Maintenance

1 shared supplement · 433 outcomes

This goal refers to people with a BMI >25 attempting to reach/maintain their ideal weight. While interventions that work for people with a BMI >25 may also work for people with a lower BMI, the context is often sufficiently different that this isn't assured.

Vertigo

1 shared supplement · 2 outcomes

Vertigo is the sensation of spinning or dizziness without any associated movement. It can be caused by conditions of the inner ear (which plays an important role in balance) or neurological conditions.

Type 2 Diabetes

1 shared supplement · 868 outcomes

Type 2 diabetes (T2D) is a disease in which blood glucose levels are too high. It is characterized by insulin resistance in muscle, fat, and pancreas cells and an inability of the pancreas to manufacture enough insulin to control blood glucose levels. T2D is strongly associated with excess body fat, and weight loss induced by lifestyle changes is extremely effective for treating T2D.

Surgical Recovery

1 shared supplement · 43 outcomes

Surgical recovery refers to physiological endpoints after surgery including recovery time and adverse events including morbidity and mortality, as well as the presence of physical pain, physical comfort with everyday activities, physical independence, psychological support, and emotional well-being.

Primary Dysmenorrhea (Menstrual Cramps)

1 shared supplement · 28 outcomes

Routine menstrual cramps are clinically called primary dysmenorrhea. Primary dysmenorrhea is menstrual pain not caused by other underlying conditions or diseases. If there is an underlying condition, such as endometriosis, that diagnosis is referred to as secondary dysmenorrhea.

Pregnancy and Delivery Health

1 shared supplement · 67 outcomes

Pregnancy and delivery health refers to infant and maternal mortality, preterm birth, infant birth weight, birth injuries, mother-infant bonding, confidence and success with breastfeeding, and a mother’s satisfaction with the birthing experience.

Pneumonia

1 shared supplement · 10 outcomes

Pneumonia is an infection that inflames the air sacs and lower airways of the lungs, causing them to fill with fluid. Signs and symptoms of pneumonia include fever and chills, difficulty breathing, fatigue, and cough (with or without mucus). Cases caused by bacteria are treated with antibiotics.

Overweight

1 shared supplement · 379 outcomes

Overweight is characterized as having a body mass index (BMI) of 25 to 29.9. Having overweight is associated with increased risk of conditions such as cardiovascular disease. However, this may not be the case in people with increased lean mass (e.g., athletes or weight lifters).